- Home
- GLSI
as of 09-04-2026 3:38pm EST
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | STAFFORD |
| Market Cap: | 244.7M | IPO Year: | 2020 |
| Target Price: | $50.00 | AVG Volume (30 days): | 116.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.65 | EPS Growth: | -18.18 |
| 52 Week Low/High: | $7.78 - $34.10 | Next Earning Date: | 05-19-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -23.91 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Stock Insider Trading Activity of Greenwich LifeSciences Inc. (GLSI)
CEO and CFO
Avg Cost/Share
$13.10
Shares
700
Total Value
$9,170.00
Owned After
5,611,402
SEC Form 4
CEO and CFO
Avg Cost/Share
$13.59
Shares
1,500
Total Value
$20,385.00
Owned After
5,611,402
SEC Form 4
CEO and CFO
Avg Cost/Share
$13.62
Shares
1,500
Total Value
$20,430.00
Owned After
5,611,402
SEC Form 4
CEO and CFO
Avg Cost/Share
$12.88
Shares
1,100
Total Value
$14,168.00
Owned After
5,611,402
SEC Form 4
CEO and CFO
Avg Cost/Share
$13.14
Shares
2,500
Total Value
$32,850.00
Owned After
5,611,402
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Patel Snehal | GLSI | CEO and CFO | Jul 29, 2026 | Buy | $13.10 | 700 | $9,170.00 | 5,611,402 | |
| Patel Snehal | GLSI | CEO and CFO | Jul 28, 2026 | Buy | $13.59 | 1,500 | $20,385.00 | 5,611,402 | |
| Patel Snehal | GLSI | CEO and CFO | Jul 27, 2026 | Buy | $13.62 | 1,500 | $20,430.00 | 5,611,402 | |
| Patel Snehal | GLSI | CEO and CFO | Jul 24, 2026 | Buy | $12.88 | 1,100 | $14,168.00 | 5,611,402 | |
| Patel Snehal | GLSI | CEO and CFO | Jul 23, 2026 | Buy | $13.14 | 2,500 | $32,850.00 | 5,611,402 |
Compare GLSI vs Leading Stocks
See how GLSI stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GLSI Greenwich LifeSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.